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A supposed role for persistent high-risk human papillomavirus (HPV) infection in 
esophageal squamous cell carcinoma (ESCC) etiology has been suggested by a number 
of studies. Concomitantly, megaesophagus induced by the Trypanosoma cruzi cell-cycle 
activity also shows a potential association with ESCC. This review discusses esophageal 
cancer and the potential association between chagasic megaesophagus and HPV as risk 
factors for ESCC development. 
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Esophageal cancer (EC) is a very aggressive tumor with high incidence and 
mortality worldwide. Approximately 500,000 new cases are diagnosed each year with 
around 406,000 deaths per year (Globocan, 2012). In Brazil, 2,860 cases are estimated 
for women and 7,950 for men in 2016 (INCA, 2016). The megaesophagus, caused by 
Chagas’ disease, is one of several risk factors for EC development. Another potential risk 
factor associated to this disease is the persistent infection of human papillomavirus 
(HPV); however, the association between HPV and megaesophagus is tentative and has 
been scarcely reviewed in the literature (Crema et al., 2010). This review aims at 
emphasizing the importance of esophageal cancer and better discuss the association of 
two of its risk factors: chagasic megaesophagus and HPV. 
 
Chagasic disease 
The American trypanosomiasis, also known as Chagas’ disease (CD), is a tropical 
parasitic disease caused by the protozoan Trypanosoma cruzi and is associated to the 
microenvironment, social and economic changes (Dias and Macedo, 2005). The highest 
occurrences are in South and Central America countries and Mexico (Machado et al., 
2012), with approximately 10 million infected people, being considered  a critical public 
health problem (Machado et al., 2012). However, non-endemic regions such as Canada, 
Europe, Australia, Japan, Spain, Portugal and United States may present some cases of 
the disease due to migration of infected individuals from Latin American (Aufderheide et 
al., 2004, Machado et al., 2012). 
The disease transmission can occur by vector, transfusion (blood and organs), 
vertical transmission (from mother to child) or contaminated food ingestion (Bonney, 
2014). The vector transmission to the human host occurs through the deposition of insect 
faeces containing the protozoon Trypanosoma cruzi while biting the host dermis 
(Giddings et al., 2006, Gutierrez et al., 2009, Rassi et al., 2010, Nagajyothi et al., 2012). 
When the faeces reach the human bloodstream, the vector lifecycle begins (Giddings et 
al., 2006, Gutierrez et al., 2009, Rassi et al., 2010, Nagajyothi et al., 2012)	(Figure 1). 
 
Figure 1. Life cycle of Trypanosoma cruzi showing the various forms of the protozoan. Adapted from the Centers for 
Disease Control and Prevention (Prevention, 2015). 
 
Chagas’ disease can be classified into two phases: acute and chronic (Kowalska 



























(Kowalska et al., 2011). In general, the acute or initial phase lasts 4 to 8 weeks, whilst 
chronic or indeterminate disease may last for 10-30 years (Nunes D. P MAL et al., 2004). 
The clinical manifestations between both phases also differ one from another, being 
discreet or undetectable in acute phase (Nunes D. P MAL et al., 2004). Normally, the 
acute symptoms include inflammation at the site of inoculation (“chagoma” inoculation), 
hepatosplenomegaly or lymphadenopathy, palpebral edema (Pomegranate signal), 
enlarged lymph nodes and splenomegaly (Rassi et al., 2010, Bonney, 2014). And, in the 
chronic phase, it can be detected in the heart, gastrointestinal organ, cardiodigestive or a 
mixed form of concomitant sites. The anatomical physiognomy changes to megacolon, 




The understanding of Chagas’ disease is important due to its o currence not being 
restricted to endemic areas (Souza et al., 1904), and since the chronic disease can cause  
the destruction of the enteric system in humans (Oliveira et al., 1998). 
Pathophysiology  
The Chagasic megaesophagus (CM) is one of the clinical manifestations of 
Chagas chronic disease. It is caused by the destruction of the myenteric plexus (plexus of 
Auerbach – parasympathetic) (Bellini et al., 2012, Gullo et al., 2012, Souza et al., 2013) 
of the esophagus that coordinates motor activity of the esophagus to the rectum, in 
response to local inflammation and immune mechanisms (Bellini et al., 2012, Souza et 
al., 2013). The destruction caused by direct parasitism of the nerve cell (action of 
neurotoxins, inflammat ry action and autoimmune mechanism) leads to achalasia. The 
neurons are in varying degrees of destruction, and there is neuritis, perineuritis and 




The mesenteric ganglionitis node is due to a crusade immunoreactivity flagellar 
antigen caused by the parasite that mimics a protein expressed by intestinal neurons, 
which attracts immune cells into the lymph nodes, leading to the disappearance and its 



























(Ribeiro-dos-Santos R et al., 1976, Adad et al., 1991). The enteric nervous system (ENS) 
is important in gastrointestinal disorders due to CD (Bellini et al., 2012, Souza et al., 
2013). The mucosal hyperplasia and muscle hypertrophy caused by plexus degeneration 
or intrinsic parasympathetic postganglionic denervation (Bellini et al., 2012, Souza et al., 
2013). The Trypanosoma cruzi causes tissue injury through direct action in target cells 
and indirectly through the induction of hypersensitivity (Hoffman and Schnitzlein, 1961, 
Gullo et al., 2012).  
The CM occurs due to achalasia of the lower sphincter (ALS), which is the 
destruction of the intramural nerve plexus leading to the absence of peristalsis and no 
harmonic opening of the lower esophageal sphincter a due to deglutition, causing food 
retention, chronic esophagitis and acanthosis; these persistent conditions may lead to 
precancerous lesions. The individuals affected often have difficulty swallowing liquids 
and solids, have regurgitation and heartburn, including chest pain, coughing and weight 
loss, and respiratory complaints that occur less frequently (Kraichely and Farrugia, 2006, 
Mabvuure et al., 2014). Additionally, individuals with CM have a wide variety of 
esophageal microbiota, consisting of anaerobic Gram-positive bacteria that are related to 
the degree of esophageal dilatation. The untreated achalasia leads to the progressive 
increase of the esophagus (megaesophagus) (Pajecki et al., 2002, Gockel et al., 2006, 
Mabvuure et al., 2014). 
Chagasic megaesophagus and esophageal cancer 
Advanced megaesophagus can increase the probability of developing esophageal 
squamous cell carcinoma (ESCC) by 3 to 8% when compared to the general population 
(Adad et al., 1991). This cancer occurs due to prolonged contact with food in the 
esophageal mucosa, also increasing bacterial growth, chemical irritation, resulting in a 
chronic esophagitis (Safatle-Ribeiro et al., 2000, Brucher et al., 2001, Pajecki et al., 2002, 
Gockel et al., 2006, Gullo et al., 2012, Tustumi et al., 2017). Carcinogenesis can be 
related to the production of nitrates and mediated by bacteria, which are present in liquid 
stasis and have mutagenic potential in the cellular DNA. The appearance of bacteria is 
another factor, which involves the appearance of epithelial dysplasia and esophageal 
cancer (Pajecki et al., 2003, Gullo et al., 2012). 
Brandalise and cols. analyzed 140 patients with megaesophagus and found that 
9.2% of them developed esophageal cancer (Brandalise et al., 1985). A study by Pinotti 



























with megaesophagus (Pinotti et al., 1980). The Trypanosoma cruzi infection is not 
sufficient to increase the occurrence of esophageal cancer in patients with CD without 
megaesophagus (Gullo et al., 2012). However, individuals with megaesophagus have the 
same risk of developing cancer as individuals with idiopathic achalasia, suggesting that 
esophageal cancer is related to achalasia and megaesophagus instead of CD (Gullo et al., 
2012). 
Individuals with chagasic megaesophagus with or without esophageal carcinomas, 
show changes in expression of p53, p16 and MIB1 (Bellini et al., 2012). Studies 
suggested that changes in TP53 in achalasia epithelium could be considered a biomarker 
to identify individuals at higher risk of developing ESCC (Bektas et al., 2001, Lehman et 
al., 2001). Other studies, using immunohistochemistry, strengthened the importance of 
p53 expression as a biomarker for precursor lesions, showing the high frequency of p53 
protein with increased expression in megaesophagus when compared to normal 
individuals (Bektas et al., 2001, Lehman et al., 2001, Bellini et al., 2008).  
A study from our group (Lacerda et al., 2017) described for the first time 
mutations in TP53 gene in patients with esophageal cancer associated with chagasic 
megaesophagus, and a high frequency of mutation found (13/32, 40.6%) suggested that 
this gene also plays an important role in carcinogenesis in this pathological condition.  
In addition, another important point is that according to some studies, HPV 
infection in patients with esophageal cancer who present mutation of the TP53 gene have 
better prognosis and response to treatment (Zhang et al., 2017). However, in relation to 
patients with chagasic megaesophagus with esophageal cancer, there are still no studies 
investigating the presence of HPV with mutation status of the TP53 gene and response to 
treatments. 
Cancer identification in patients with megaesophagus is difficult because the 
symptoms are hampered and frequently totally masked by severe dysphasia caused by the 
disease. The diagnosis is consequently delayed, mainly when the individual is in 
advanced stage leading to a poor prognosis (Bellini et al., 2010). 
Few studies have addressed the genetic changes concurrent with megaesophagus; 
genetic alterations associated with cell cycle regulation similar to those that occur in 
esophageal carcinoma have been suggested consistent with a role for megaesophagus in 































 Approximately 500 thousand new cancer cases of cancers are diagnosed annually 
and account for more than 400 thousand deaths annually, with the vast majority of them 
occurring in developing countries (Globocan, 2012, Zhang et al., 2015). Esophageal 
cancer (EC) is reported as the eighth most common cancer in both genders and the sixth 
leading cause of death worldwide (Globocan, 2012). A greater incidence of esophageal 
cancer has been reported, since 1960, in northern Iran to north-central China, considering 
this region as the "esophageal cancer belt" (Mahboubi et al., 1973, Ferlay et al., 2008, 
Gholipour et al., 2008, Roshandel et al., 2014, Xu et al., 2015, Zhang et al., 2015) while 
Brazil, Chile and South African countries are also considered high risk areas (Lopes and 
Fagundes, 2012, Zhang et al., 2015). The prognosis and diagnosis are unprofitable 
because of the lack of specific symptoms early in the illness, with a global survival of less 
than 20% (Lopes and Fagundes, 2012, Zhang et al., 2015).  
 According to the Brazilian National Cancer Institute (INCA), the estimate of 
esophageal cancer in 2016 in Brazil is 2,860 cases in women and 7,950 in men (INCA, 
2016). The prevalence of esophageal cancer among Brazilian regions is varied, the South 
region the being 5th most frequent in men, followed by the Central West (6th) and the 
Southeast and Northeast in 11th (INCA, 2016). For women, the South is the 11th most 
common, followed by Southeast and Northeast (13th) and the Central West and North in 
14th (INCA, 2016). In addition, the Rio Grande do Sul State represents a higher risk for 
developing ESCC due to factors such as smoking, alcohol, hot foods and hot drinks 
consumption (Souto Damin et al., 2006, Antunes et al., 2013). 
 
Esophageal squamous cell carcinoma (ESCC) 
 ESCC and esophageal adenocarcinoma (EAC) are the major types of esophageal 
cancer; ESCC is the most predominant histologic type found in African-descendent 
patients and EAC in Caucasians (Lin et al., 2011, Zhang, 2013). EC patients present an 
overall survival of five years when exposed to treatment (90%), but this rate decreases 
dramatically (20%) in patients in the late stage (Dawsey, Lewin, Liu, et al., 1994, 
Dawsey, Lewin, Wang, et al., 1994, Shimizu et al., 2002, Rice et al., 2009, Siegel et al., 



























 There are many risk factors to the ESCC development, such as food intake, hot 
beverages, smoking habit (most important), high ingestion of red meat, canned foods, 
achalasia and virus infections, as human papillomavirus (HPV) (Bosetti et al., 2000, 
Islami et al., 2009, Liyanage et al., 2014). 
 
Human papillomavirus (HPV) 
HPV Biology 
 HPV belongs to the Papillomaviridae family, which comprise a group of small 
viral double-stranded DNA that are sexually transmitted among individuals (Jin and Xu, 
2015, Lorenzi et al., 2015).  
 The genome of HPV is divided into three regions (Open Reading Frames - ORF):  
early (E), late (L) and control region, and a non-coding region. The early region is  
composed by the E1, E2, E4, E5, E6 and E7 genes; the L1 and L2 genes are responsible 
for viral reorganization, forming the viral capsid and allowing a new infection to complete 
their life cycle (Zheng and Baker, 2006). The L1 gene is responsible for remaking the 
capsid and the L2 gene function is to reorganize and rebuild the viral body (Doorbar, 
2005). The E1 and E2 genes encode important proteins for viral DNA replication and 
gene transcription. The E4 protein is expressed in the later stages and is important in 
altering the intracellular matrix, maturation and release of new virus particles. The E6 and 
E7 proteins are involved in virus amplification. The late regions L1 and L2 encode viral 
proteins in the later stages of viral replication (Scheurer et al., 2005, Munoz et al., 2006).  
 The infection cycle occurs in five steps:  infection, maintenance of the genome, 
proliferative phase, genomic amplification and synthesis and release of new viral particles 
(Doorbar, 2005). There are more than 200 HPV types; based on their capacity to induce 
cell immortalization these are divided in two groups: low-risk and high risk. (de Villiers, 
Fauquet, et al., 2004, Zheng and Baker, 2006, Van Doorslaer et al., 2013). HPV as a 
cause of cervical cancer was first suggested in the 70s by Harald zur Hausen. In addition, 
HPV infection may contribute to approximately 5% of all human cancers (de Villiers, 
Fauquet, et al., 2004, Zheng and Baker, 2006, Van Doorslaer et al., 2013).  
 
HPV Oncogenesis 
Currently, over 200 HPV (http://pave.niaid.nih.gov/) types are described, are 



























verrucas (Nguyen et al., 2014). The other genus α-HPV are classified as low (6 and 11, 
among others) and high-risk (16, 18, 51, 56, 31, 33, 45, etc.) according to the capacity to 
induce malignant lesions (Li et al., 2014, Jin and Xu, 2015, Lorenzi et al., 2015). The role 
of high-risk HPV in cervical cancer development is well-defined (Castillo et al., 2011). 
Among the HPV types, HPV16 and HPV18 are the most frequent, accounting for around 
70% of cases (Castillo et al., 2011). The integration of viral DNA in the host cells is one 
of the factors associated to carcinogenesis, because most cervical cancers contain 
integrated viral genome fragments (Durst et al., 1987).  
HPV-induced cancer is a result of a complex cascade of events that integrate 
different molecules that affect cell cycle regulation, among other biological phenomena. 
In brief, the HPV genome integration in the host cells leads to abnormal expression of E6 
and E7 oncoproteins (Doorbar, 2005). The E7 oncoprotein interacts with the pRB, 
displaces the E2F transcription factor, inducing the cell to continue to proliferate 
uncontrollably (Doorbar, 2005). However, more recently, it has been shown that E2 
methylation also limits E2 expression in HPV-related neoplasms (Chaiwongkot et al., 
2013).  The oncoprotein E6 targets p53 leading to its degradation by preventing DNA 
repair and apoptosis and positively regulates the expression of telomerase, causing the 
cells to replicate perpetually (Figure 3) (Doorbar, 2005). Furthermore, the E5 oncoprotein 
indirectly contributes to the amplification of the genome by altering the environment of 
the host cell by regulating vascular endothelial growth factor (VGFR) through the EGFR 
MEK/ERK 1, 2 and PI3K, thus contributing to tumorigenesis (Doorbar et al., 2012, 
Liyanage et al., 2014, Al Moustafa, 2015).  
However it is worth mentioning that the HPV infection model is well defined for 
cervical and head and neck cancers, but not for ESCC (Doorbar, 2005). In addition, a 
previous published review by our group addressed the issues related to the disease burden 
caused by cervical cancer and precursor lesions in Brazil related to HPV (Lorenzi et al., 
2015). 
 
Figure 3. Representation of HPV infection in host cell. Adapted from Westra WH (Westra, 2014). 
	
Esophageal cancer and HPV 
The role of infectious agents has been suggested as a risk factor for the 



























Moreover, recent studies suggest that carcinogenesis caused by HPV in cervical 
cancer is due to the "tropism" that HPV is by residual embryonic cells in the 
squamocolumnar junction (SCJ) (epithelial cells that book lie underneath the columnar 
epithelium of the endocervix).These cells and their importance for cervical HPV-induced 
squamous cell carcinoma (SCC) were identified further to the discovery of residual 
embryonic cells in the esophogastric (SCJ) (Nguyen et al., 2014, Herfs and Crum, 2015). 
So it should be emphasized the importance of investigating the presence of HPV in 
esophageal tissue, since these cells were also found in the esophagus.  
Syrjänen and cols. (Syrjanen, 1982) suggested in the early 80s the association 
between HPV and esophagus cancer  in a histological study that showed the presence of 
HPV in 40% of Finnish patients with ESCC (Syrjanen, 1982). 
Estimates of HPV as a risk factor for esophageal cancer vary greatly among 
different studies (Syrjanen, 2002). This variation may be explained by different sampling 
methods, anatomical sites, ethnic and demographic factors and the type of methodology 
used for HPV detection (Li et al., 2014). Therefore the International Agency for Research 
on Cancer (IARC) has recognized the involvement of HPV in head and neck tumors, but 
no conclusion has been announced, however, in relation to HPV and ESCC, being 
necessary more studies in the area (Liyanage, Segelov, et al., 2013). 
Techniques used for HPV detection in ESCC 
Various techniques have been used in the research field to find HPV evidence in 
ESCC. In the 1980s the technique often used was in situ hybridization (ISH); however, 
ISH showed a low sensitivity and specificity (Syrjanen, 2002). So, tests with enhanced 
sensitivity and specificity began to be used as real-time PCR (qPCR) (Xu et al., 2004, 
Wang et al., 2010, Liu et al., 2012, Antunes et al., 2013, Liyanage et al., 2014). Another 
method used in HPV identification is the ELISA test (Xu et al., 2004, He et al., 2014). 
Schmitt and cols. developed the multiplex HPV genotyping (MPG), which allows 
the simultaneous detection and genotyping of up to 100 types of HPV in a sample 
(Schmitt et al., 2006). Additionally, it is a sensitive technique for detection of HPV in 































Positive and negative association between HPV and ESCC 
Studies in the years 1992 to 2013 reported the presence of HPV in ESCC in Asia 
and Europe (26.3%) and American countries (14%). Moreover, high-risk regions in China 
(Anyang, Xinjiang, Sichuan) showed the same correlation between the HPV and ESCC 
patients. (Cao et al., 2014, Chen et al., 2014, He et al., 2014). 
He and cols. (He et al., 2014) analyzed 1,435 samples of patients with ESCC 
Anyang in China, and showed the presence of the HPV16 E7 oncoprotein with a higher 
risk of developing ESCC. Chan and cols. screened the HPV types in ESCC patients from 
Kazakh and Xinjiang regions in China, and showed that the HPV infection accounted for 
66.7% and 97.72% HPV16 and 2.27% HPV18 (Chen et al., 2014). Liyanage and cols. 
performed a case-control study in 99 Australian ESCC patients and 100 healthy 
individuals and suggested that HPV may be an additional risk factor for the ESCC 
development (Liyanage et al., 2014). In addition, a recent study of The Cancer Genome 
Atlas (TCGA) concluded that HPV cannot be considered as an etiological factor for 
ESCC because of the paucity of HPV mRNA transcripts detectable among ESCCs 
(Cancer Genome Atlas Research et al., 2017). 
According to the study by Evans and cols (Evans et al., 2011), we can classify 
HPV in "passengers" and "drivers" Driver HPV infections are meaningful in the lesion, 
however passenger HPV refers to opportunistic infection that is incidental to 
tumorigenesis may be present in only a few cells within the tumor; suggesting that some 
techniques, such as PCR, may be inappropriate to associate the presence of HPV as the 
cause of the tumor (Evans et al., 2011). 
The meta-analyses made by Syrjanen (Syrjanen, 2013) show some studies that 
associate HPV presence in the esophageal mucosa with ESCC according to region, and 
thus can be observed the high incidence of HPV-positive in ESCC in the regions of China, 
Japan and Africa, high-risk areas, corroborating what is described in the literature. 
Moreover, it can also be seen that the regions considered low risk such as Australia, the 
USA and Italy show the presence of HPV in patients with ESCC, suggesting the 
importance of further studies on the role of HPV (especially mRNA expression) in ESCC 
(Table 1). Besides that the meta-analyses show studies that do not associate HPV presence 
in esophageal mucosa with and without ESCC, the great majority of regions are 




























Table 1 - HPV positive in ESCC patients. Adapted from (Syrjanen, 2013). 
 
Author 






HPV positive  
Method n/total % 
      




(Yao et al., 2006) China 16, 18 59/82 72 IHC 
(Li et al., 1991) China 16 12/24 50 SB 
(Chang et al., 1992) China 11, 16, 18, 30 8/20 40 SB 
(Chang et al., 1990) China 6, 11, 16, 18 25/51 49 HB 
(He et al., 1996) China 16, 18 37/103 36 SB, PCR 
(Brooks et al., 1987) China 6, 11, 16, 18 22/51 43 ISH 
(Chang et al., 1993) China 6, 11, 16, 18, 30 85/363 23 ISH 
(Zhu et al., 2005) China 16 86/119 72 ISH 
(Chang F  et al., 2000) China 





(Qi et al., 2006) China 16, 18 24/60 40 ISH 
(Yao et al., 2006) China 16, 18 23/82 28 ISH 
(Chang et al., 1992) China 6, 11, 16, 18 25/51 49 PCR 
(Chen, 1993) China CP 24/40 60 PCR 
(Chen et al., 1994) China GP 24/40 60 PCR 
(He et al., 1997) China 16, 18 32/152 21 PCR 
(Lavergne and de Villiers, 1999) 
China,  
S. Africa 
CP 19/63 30 PCR 
(de Villiers et al., 1999) China CP 20/117 17 PCR 
(Chang et al., 2000) China CP 17/101 17 PCR 
(Shen et al., 2002) China CP 115/17
6 
66 PCR 
(Liu et al., 2003) China CP 28/152 18 PCR 
(Xu et al., 2003) China CP 28/40 70 PCR 
(Zhou et al., 2003) China CP 31/48 63 PCR 
(Si et al., 2003) China CP, 16, 18 43/319 14 PCR 
(de Villiers, Gunst, et al., 2004) China CP 20/30 67 PCR 
(Lu et al., 2004) China SP, 16 55/104 53 PCR 
(Si et al., 2005) China SP, 16 35/35 100 PCR 
(Liu et al., 2005) China SP, 16 24/40 60 PCR 
(Cao et al., 2005) China CP, 16, 18 207/26
5 
78 PCR 





























Table 1 - (Continued). 
 
Author 







Method n/total % 
      
(Zhou et al., 2007) China SP, 16 97/161 60 PCR 
(Liu et al., 2007) China 16, 18 61/112 50 PCR 
(Lu et al., 2008) China Various 20/67 30 INNO-Lipa 
(PCR) 
(Yang et al., 2008) China SP 16, 18 308/435 71 PCR 
(Zhao et al., 2009) China CP, SP 16, 18 37/42 88 PCR 
(Zhang et al., 2010) China SP 16, 18, 58 35/70 50 PCR 
(Wang et al., 2010) China SP, genotyping 244/435 56 PCR 
(Wang et al., 2010) China 16 35/69 51 PCR 
(Ding et al., 2010) China GP 8/17 47 PCR 
(Zhang et al., 2011) China CP, genotyping 82/106 77 PCR 
(Cui et al., 2011) China 16, 18 18/18 100 PCR 
(Furihata et al., 1993) Japan 6, 11, 16, 18, 
31, 33 
24/71 34 ISH 
(Ono et al., 1994) Japan 16, 18 13/42 31 ISH 
(Takahashi et al., 1998) Japan 6, 11, 16, 18 37/123 30 ISH 
(Shibagaki et al., 1995) Japan CP 15/72 21 PCR 
(Khurshid et al., 1998) Japan CP, 16, 18 17/27 63 PCR 
(Kawaguchi et al., 2000) Japan CP 12/75 16 PCR 
(Hasegawa et al., 2002) Japan CP 20/48 42 PCR 
(Goto et al., 2011) 
Japan, Taiwan, 
Singapore  
PC, HR-HPV 17/181 9 PCR, ISH 
(Castillo et al., 2011) Japan, Pakistan, 
Colombia 
SP 16 24/166 14 PCR 
(Sobti et al., 2001) India CP 25/40 63 PCR 
(Katiyar et al., 2005) India SP 16, 18 27/101 27 PCR 
(Hussain et al., 2009) India SP 16, 18 14/75 19 PCR 
(Hussain et al., 2011) India GP 14/75 19 PCR 
(Gupta et al., 2012) India CP 17/49 35 PCR 
(Cooper et al., 1995) S. Africa 
6, 11, 18, 31, 
33 
25/48 52 ISH 






























Table 1 - (Continued). 
Author 
(year and ref.) Country HPV types 
HPV positive 
Method n/total % 
      
(Williamson et al., 1991) S. Africa Various 6/14 43 PCR 
(Matsha et al., 2002) S. Africa CP, SEQ, 11, 
39, 52 
23/50 46 PCR 
(Kim WH et al., 1991) Korea 16, 18 16/24 67 PCR 
(Farhadi et al., 2005) Iran CP, 16, 18 14/38 37 PCR 
(Far et al., 2007) Iran CP 33/140 24 PCR 
(Suzuk et al., 1996) USA 6, 16, 18 1/23 4 PCR 
(Kamath et al., 2000) USA CP 1/22 5 Reverse line 
(Doxtader EE and L, 
2012) 
USA HR-HPV 1/6 17 ISH 
(Hippelainen et al., 1993) Finland - 11/61 18 HB, ISH 
(Syrjanen, 1982) Finland - 24/60 40 HB 
(Benamouzig et al., 1992) France 6/11, 16/18 5/12 12 DB 
(Kulski et al., 1986) Australia 11, 13, 16, 18 5/10 50 FISH 
(Kulski et al., 1990) Australia 6, 11, 16, 18 9/39 23 HISTOFISH 
(Antonsson et al., 2010) Australia CP, genotyping 8/222 4 PCR 
(Lambot et al., 2000) Belgium  CP 1/21 2 PCR 
(Acevedo-Nuno et al., 
2004) 
Mexico CP 15/17 88 PCR 
(Herrera-Goepfert et al., 
2009) 
Mexico CP 15/60 25 PCR 
(Astori et al., 2001) Italy CP, RFLP 8/17 47 PCR 
(Tornesello et al., 2009) Italy SP 10/36 28 PCR 
(Gabor et al., 2006) Hungary SP 16, 18, SB 6/26 23 PCR 
(Bognar et al., 2008) Hungary SP 16, 18 6/26 23 PCR 
      
CP, consensus primers; DB, dot blot hybridization; FISH, filter in situ hybridization; GP, general primers; HB, 
histological biopsy; HISTOFISH, histology-filter in situ; HR, high-risk types; HRA, high-risk area; IHC, 
immunohistochemistry; ISH, in situ hybridization; IS-PCR, in situ-polymerase chain reaction; LR, low-risk types; 
PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SB, Southern blot 





























Table 2 - HPV negative in ESCC patients. Adapted from (Syrjanen, 2013). 
 
Author 









      
(Kuwano et al., 2001) Japan Ag 0/4 0 IHC 
(Akutsu N  et al., 1995) Japan CP 0/31 0 PCR 
(Saegusa et al., 1997) Japan CP, 16, 18 0/103 0 PCR 
(Loke SL  et al., 1990) 
Hong 
Kong 
6, 11, 16, 18 0/37 0 DB 
(Lu et al., 1995) China 16, 18 0/35 0 SB, PCR 
(Gao et al., 2006) China HR 0/4 0 HCII 
(Ashworth et al., 1993) UK 
6, 11, 16, 18, 
31, 33 
0/4 0 ISH 
(Morgan et al., 1997) UK - 0/22 0 PCR 
(De Petris et al., 2005) USA Wide spectrum 0/2 0 ISH 
(Kiyabu MT  et al., 1989) USA 16/18 0/13 0 PCR 
(Paz et al., 1997) USA - 0/11 0 PCR 
(Baines et al., 2005) USA CP 0/22 0 PCR 
(Bellizzi et al., 2009) USA HR-HPV 0/9 0 ISH 
(Malik et al., 2011) USA HR-HPV 0/32 0 ISH 
(Landau et al., 2012) USA HR-HPV 0/9 0 ISH 
(Benamouzig et al., 1995) France 6, 11, 16, 18, 31, 33 0/75 0 PCR 
(Benamouzig R  et al., 1996) France - 0/75 0 PCR 
(Regragui et al., 2004) France CP 0/1 0 PCR 
(Smits et al., 1995) Holland CP 0/61 0 PCR 
(Kok TC  et al., 1997) Holland CP 0/63 0 PCR 
(Rugge et al., 1997) Italy - 0/18 0 PCR 
(Talamini et al., 2000) Italy CP, 16, 18 0/45 0 PCR 
(Poljak M  et al., 1998) Slovenia CP, 6, 16, 18 0/121 0 PCR 
(Lewensohn-Fuchs et al., 1994) Sweden GP 0/10 0 PCR 
(Awerkiew et al., 2003) Germany CP 0/23 0 PCR 




(Koh et al., 2008) Korea 16, 18, 31, 33, 35, 52, 58 0/129 0 PCR 
      
Ag, HPV antigens; CP, consensus primers; DB, dot blot hybridization; GP, general primers; HCII, hybrid 
capture 2; HR, high-risk types; IHC, immunohistochemistry; ISH, in situ hybridization; PCR, polymerase 






























In Brazil, a region considered at high risk for the development of esophageal 
cancer (de Barros et al., 1999), few studies have investigated the presence of HPV in 
patients with and without ESCC, as shown in Table 3. These studies failed to establish an 
association between HPV and ESCC, being extremely important more studies to prove 
the presence of HPV in patients with ESCC. 
 
Table 2 - Brazilian studies that analyzed the presence of HPV in patients with ESCC. 
 
Author 








Method n/total % n/total % 
        
(Weston and Prolla, 2003) HR and LR 1/40 2.5  1/10 10 HCII 
(Souto Damin et al., 2006) 




0/26 0 PCR 
(Herbster et al., 2012) 16, 18, 66 34/264 13  - - PCR, ISH 
(Antunes et al., 2013) HPV L1 0/52 0  0/122 0 PCR 
(Pastrez et al., 2017) Various 12/87 13.8  12/87 13.8 Luminex 
        
CP, consensus primers; SEQ, sequencing; HCII, hybrid capture 2; HR, high-risk types; ISH, in situ hybridization; 
PCR, polymerase chain reaction; LR, low-risk types. 
 
HPV and chagasic megaesophagus 
The presence of HPV in ESCC patients has been associated especially in high risk 
areas (Liyanage, Rahman, et al., 2013). It is known that individuals with achalasia have 
a high risk to develop ESCC (Tustumi et al., 2017). However, the prevalence of HPV in 
patients with megaesophagus has not been explored (Crema et al., 2010). As far as we 
know, just one Brazilian study addressed the association between megaesophagus and 
HPV (Crema et al., 2010). According to Crema et al. 63.3% (19/30) of patients HPV 
positive also presented achalasia and 16.7% (3/18) did not present megaesophagus. The 
predominant HPV type was HPV16 in 15/22 followed by HPV18 in 4/16 positive 
patients. In addition, HPV was present in most patients with grades III and IV 






























 Considering what was discussed in this review, we observed that esophageal 
cancer is an aggressive tumor with high mortality in the world, being the squamous cell 
carcinoma subtype the most frequent, being the knowledge of its risk factors fundamental 
to aid in prevention strategies and even in the early detection of this malignancy. Among 
the several risk factors presented, we highlight the megaesophagus of Chagas’ etiology 
(mainly degrees III and IV), and HPV as a possible cause, however its incidence varies 
greatly between studies. Thus, we have shown that more studies are essential to clarify 
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